ASCO 2022
The success of ADCs raises questions about patient selection
June 2022
Summary
Scientific Presentation with Prof. John Bartlett reviewing the current data on how the success of ADCs raises questions about patient selection and identification of responders.
Highlights
- 1
Highly effective antibody-drug conjugates (ADCs) are impacting clinical practice
- 2
The level of target expression for successful ADC targeting remains unknown
- 3
Present assays are predicated on measurement of biological pathway effects (esp for HER2) and may underestimate responsive populations
- 4
Precise mechanisms of action and resistance unknown
- 5
Further work required to match patients to optimal ADC approaches
Comments (0)